← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents
calaspargase pegol
L01XX86
Forms & Strengths
- Injection: 1000 U/mL
- Single-dose vial
Adult Dosing
- 2.5 mg/m² IV every 14 days
- Dose adjustment may be required based on asparaginase activity levels and clinical response
Pediatric Dosing
- 2.5 mg/m² IV every 14 days for patients 1 month to 21 years
- Dose adjustment may be required based on asparaginase activity levels and clinical response
Indications
- Acute lymphoblastic leukemia (ALL) as a component of a multi-agent chemotherapeutic regimen
- First-line treatment of pediatric and adult patients with ALL
Mechanism of Action
- Pegylated L-asparaginase enzyme depletes L-asparagine in the bloodstream and lymph nodes
- Lack of L-asparagine inhibits protein synthesis in rapidly dividing cells, such as leukemic blasts
Contraindications
- History of serious hypersensitivity reaction to calaspargase pegol or any other L-asparaginase product
- Severe or life-threatening pancreatitis with prior L-asparaginase therapy
Adverse Reactions
- Hypersensitivity reactions (anaphylaxis, angioedema, urticaria)
- Pancreatitis
- Hepatotoxicity
- Thrombosis
- Hemorrhage
- Neurotoxicity
Drug Interactions
- Inhibited by glucocorticoids
- Concurrent use with vincristine may increase risk of hepatotoxicity
- Monitor for increased risk of thrombosis when used with other thrombogenic agents
Curated Content: Needs Vetting Before Put to Clinical Use